Of note, the expressions of PD-1, PD-L1, and CTLA4 were all significantly upregulated in the ALOX12 highly expressed group (P < 0.0001), revealing the encouraging application value of immune checkpoint blockade (ICB) in CRC patients with a high ALOX12 expression. The gene discussed is ALOX12; the disease is colorectal carcinoma.